每经编辑｜陈柯名 9月29日，一女子在社交平台发帖称，自己应聘得力集团某岗位并通过了三轮面试，但在入职当天被发现跛脚，遭HR建议离职。该网帖引发关注后，疑似 得力集团CEO陈雪强的账号在网帖评论区留言致歉。30日，该女子回应称，得力总裁办主任联系了自己，邀请其面聊，但被她拒绝了。当事人表示，她已 经拒绝了得力的再入职邀请，目前不会考虑再去得力工作。同日，得力集团客服表示，该网帖上的留言确系CEO本人回复，集团将发布公告。 当事人发帖讲述事情经过。 网络图 此前，一名经四轮面试入职滴滴策略运营岗的残疾员工因走路稍有跛脚，被HR劝退离职，后涉事HR被滴滴公司开除。据上述网帖的作者称，自己的经历 与这起滴滴事件的当事人有相似之处：她经三轮面试获得了得力集团某岗位的入职资格。当她满心欢喜前往得力集团宁波总部报到时，却因走路跛脚这一 情况，被接待的工作人员询问腿部问题。 尽管当事人明确表示，这并不影响工作，但当天下午就被知领导不同意其入职，甚至被要求在微信上发送"因不适应，主动离开"的消息。据网帖作者表 示，她小时候腿部曾患疾病导致走路跛脚，但跛脚的程度无需拐杖以及轮椅辅助。她称，自己已有7年职场经历，多次升职。"过往 ...

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [2] - Bee Assistant plans to raise up to 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [3] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] Group 2 - Three squirrels received approval from the China Securities Regulatory Commission for H-share issuance, planning to issue up to 81.5483 million shares [5] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [6] - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind and solar energy [7] Group 3 - Sainz's subsidiary plans to invest up to 300 million yuan in the expansion of selection and extraction agents [8] - Hunan YN reported no significant changes in its internal and external operating environment [9] - Electric Power Investment plans to restructure assets and has received a notice from the Shenzhen Stock Exchange to suspend review [10] Group 4 - Guanzhong Ecology is in the planning stage to acquire 51% of Hangzhou Actuary [11] - Aima Technology announced the transfer and suspension of production capacity at its subsidiary in Guangdong [12] - Fosun Pharma's subsidiary received approval for clinical trials of a new drug [13] Group 5 - EVE Battery Investment received a cash dividend of 375 million HKD from its indirect associate, Simoer International [14] - Shanmei International announced a change in its board leadership due to personnel changes [15] - Weiye Co. announced the resignation of its chairman for personal reasons [16] Group 6 - Jiaoda Sinuo's chairman is under detention, and the company has appointed a new acting chairman [17] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [18] - ST Zhengping's stock price has seen an abnormal increase, leading to a suspension for investigation [19] Group 7 - Daqian Ecology's shareholder plans to reduce its stake by up to 3% [20] - Rundat Medical's shareholders plan to collectively reduce their stake by up to 2.99% [21] - Seli Medical's shareholder plans to reduce its stake by up to 2% [22] Group 8 - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [23] - Zhongwu Drone signed a significant contract worth 615 million yuan for drone systems [24]

标签： 财经频道 财经资讯 人民财讯9月30日电，润达医疗(603108)9月30日公告，公司股东朱文怡及公司董事、高级管理人员 刘辉拟通过大宗交易或集中竞价交易方式合计减持不超2.99%公司股份。朱文怡及刘辉系母子关系。 (资料图片) ...

智通财经APP讯，润达医疗(603108.SH)发布公告，公司股东朱文怡及刘辉拟在公告之日起15个交易日 后的三个月内通过大宗交易或集中竞价交易方式减持股份，拟合计减持不超2.99%公司股份。 ...

润达医疗（603108）(603108.SH)发布公告，公司股东朱文怡及刘辉拟在公告之日起15个交易日后的三 个月内通过大宗交易或集中竞价交易方式减持股份，拟合计减持不超2.99%公司股份。 ...

人民财讯9月30日电，润达医疗（603108）9月30日公告，公司股东朱文怡及公司董事、高级管理人员刘 辉拟通过大宗交易或集中竞价交易方式合计减持不超2.99%公司股份。朱文怡及刘辉系母子关系。 ...

证券代码：603108 证券简称：润达医疗 公告编号：临 2025-052 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司 股东及董监高减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东及董监高持股的基本情况 截至本公告披露日：股东朱文怡持有上海润达医疗科技股份有限公司（以下 简称"公司"、"润达医疗"）股份共计 31,518,408 股，占公司总股本 5.22%。公 司董事、高级管理人员刘辉持有公司股份共计 31,528,771 股，占公司总股本 5.22%。 减持计划的主要内容 公司股东朱文怡及刘辉拟在本公告之日起 15 个交易日后的三个月内通过大 宗交易或集中竞价交易方式减持股份。 | 股东 | 减持数量 | | 占公司总股份数 | | --- | --- | --- | --- | | 朱文怡 | 不超过：10,540,000 | 股 | 不超过：1.75% | | 刘辉 | 不超过：7,460,000 | 股 | 不超过：1.24% | 股东后 ...

格隆汇9月30日丨润达医疗(603108.SH)公布，公司股东朱文怡及刘辉拟在本公告之日起15个交易日后的 三个月内通过大宗交易或集中竞价交易方式减持股份。其中，朱文怡减持不超过1054万股，不超过 1.75%；刘辉减持不超过746万股，不超过1.24%。 ...

Core Viewpoint - Shanghai RunDa Medical Technology Co., Ltd. announced a share reduction plan by shareholders and executives, indicating personal financial needs as the reason for the reduction [1] Shareholder and Executive Holdings - Shareholder Zhu Wenyiyi holds 31,518,408 shares, accounting for 5.22% of the total share capital [1] - Executive Liu Hui holds 31,528,771 shares, also accounting for 5.22% of the total share capital, and they are in a mother-son relationship [1] Reduction Plan Details - Zhu Wenyiyi plans to reduce holdings by no more than 10,540,000 shares (up to 1.75%) [1] - Liu Hui plans to reduce holdings by no more than 7,460,000 shares (up to 1.24%) [1] - The reduction will occur within three months starting from 15 trading days after the announcement, specifically from October 30, 2025, to January 29, 2026 [1] Uncertainty and Control - The number of shares to be reduced will be adjusted according to ex-rights and ex-dividend matters, indicating some uncertainty in the plan [1] - The share reduction will not lead to a change in the company's control [1]

Group 1 - The core point of the article is that RunDa Medical (603108.SH) announced that shareholders Zhu Wenyi and Liu Hui plan to reduce their holdings of shares within three months through block trading or centralized bidding after 15 trading days from the announcement date [1] - Zhu Wenyi intends to reduce holdings by no more than 10.54 million shares, which accounts for up to 1.75% of the total shares [1] - Liu Hui plans to reduce holdings by no more than 7.46 million shares, representing up to 1.24% of the total shares [1]